标题
Therapeutic pipeline in nonalcoholic steatohepatitis
作者
关键词
-
出版物
Nature Reviews Gastroenterology & Hepatology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-02-11
DOI
10.1038/s41575-020-00408-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens
- (2020) Juan Pablo Frias et al. DIABETES OBESITY & METABOLISM
- Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
- (2020) Mansoor Husain et al. DIABETES OBESITY & METABOLISM
- Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring
- (2020) Hani Shamseddeen et al. DRUG SAFETY
- Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis
- (2020) Cristy R.C. Verzijl et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
- (2020) Vlad Ratziu et al. HEPATOLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- Update on NAFLD genetics: from new variants to the clinic
- (2020) Eric Trépo et al. JOURNAL OF HEPATOLOGY
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials
- (2020) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study
- (2020) Arthur Bergman et al. Clinical Pharmacology in Drug Development
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
- (2020) Mark L. Hartman et al. DIABETES CARE
- Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
- (2020) Stephen A. Harrison et al. GASTROENTEROLOGY
- Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
- (2020) Beth A. Davison et al. JOURNAL OF HEPATOLOGY
- A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study
- (2020) Stephen A Harrison et al. Lancet Gastroenterology & Hepatology
- Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers
- (2020) Stephen A. Harrison et al. Contemporary Clinical Trials
- Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial
- (2020) Rohit Loomba et al. JOURNAL OF HEPATOLOGY
- EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a argon-1 study
- (2020) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting
- (2020) Kim Huard et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC
- (2019) Michael Trauner et al. HEPATOLOGY
- Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand
- (2019) Luis Calzadilla-Bertot et al. LIVER TRANSPLANTATION
- Diagnosis and Management of Statin Intolerance
- (2019) Rodrigo Alonso et al. Journal of Atherosclerosis and Thrombosis
- NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis
- (2019) Stephen A. Harrison et al. HEPATOLOGY
- A novel heterozygous ABCB 4 , RUNDC 3B and ABCB 1 deletion associated with severe cholestatic liver disease in adulthood
- (2019) Benedetta Terziroli Beretta‐Piccoli et al. HEPATOLOGY
- The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
- (2019) Arun J. Sanyal et al. HEPATOLOGY
- LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial
- (2019) Rohit Loomba et al. JOURNAL OF HEPATOLOGY
- SAT-352-A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis
- (2019) Eric Lawitz et al. JOURNAL OF HEPATOLOGY
- SAT-299-Assessment of NIS4 clinical utility for identification of patients with active NASH (NAS ≥ 4) and significant fibrosis (F ≥ 2) in patients at risk of NASH
- (2019) Remy Hanf et al. JOURNAL OF HEPATOLOGY
- SAT-357-Tropifexor, a farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis: Interim results based on baseline body mass index from first two parts of Phase 2b study FLIGHT-FXR
- (2019) Arun Sanyal et al. JOURNAL OF HEPATOLOGY
- Outcomes of Liver Transplantation for Non-alcoholic Steatohepatitis: a European Liver Transplant Registry Study
- (2019) Debashis Haldar et al. JOURNAL OF HEPATOLOGY
- GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH
- (2019) Zobair Younossi et al. JOURNAL OF HEPATOLOGY
- Past, present and future perspectives in nonalcoholic fatty liver disease
- (2019) Arun J. Sanyal Nature Reviews Gastroenterology & Hepatology
- From NASH to HCC: current concepts and future challenges
- (2019) Quentin M. Anstee et al. Nature Reviews Gastroenterology & Hepatology
- Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis
- (2019) Eduardo Vilar-Gomez et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
- (2019) Upendra Kaul et al. Cardiovascular Diabetology
- Epidemiology of chronic liver diseases in the USA in the past three decades
- (2019) Zobair M Younossi et al. GUT
- Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD
- (2019) Mary E. Rinella et al. HEPATOLOGY
- Obeticholic acid may increase the risk of gallstone formation in susceptible patients
- (2019) Samer Al-Dury et al. JOURNAL OF HEPATOLOGY
- Bariatric surgery is associated with reduction in non-alcoholic steatohepatitis and hepatocellular carcinoma: A propensity matched analysis
- (2019) Minyoung Kwak et al. AMERICAN JOURNAL OF SURGERY
- REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
- (2019) Vlad Ratziu et al. Contemporary Clinical Trials
- Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in NAFLD
- (2019) Veeral H. Ajmera et al. HEPATOLOGY
- Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
- (2019) Rohit A. Sinha et al. THYROID
- The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease
- (2019) James M. Paik et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
- (2019) Lindsay E. Clegg et al. Cardiovascular Diabetology
- PNPLA3 I148M and liver fat and fibrosis scores predict liver disease mortality in the United States population
- (2019) Aynur Unalp‐Arida et al. HEPATOLOGY
- Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- New insights into managing symptoms during statin therapy
- (2019) Jennifer G. Robinson PROGRESS IN CARDIOVASCULAR DISEASES
- Low Testosterone Is Associated With Nonalcoholic Steatohepatitis (NASH) and Severity of NASH Fibrosis in Men With NAFLD
- (2019) Monika Sarkar et al. Clinical Gastroenterology and Hepatology
- A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
- (2019) Marcos Pedrosa et al. Contemporary Clinical Trials
- Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
- (2019) Naga Chalasani et al. GASTROENTEROLOGY
- Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
- (2019) Guadalupe Garcia-Tsao et al. JOURNAL OF HEPATOLOGY
- A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
- (2019) Mohammad Shadab Siddiqui et al. JOURNAL OF HEPATOLOGY
- Reply to: “The reported ‘clear cut time association between interferon-free treatment and HCC’ is anything but clear cut”
- (2019) Victor Sapena et al. JOURNAL OF HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
- (2019) Michael K. Badman et al. Clinical Pharmacology in Drug Development
- NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances
- (2018) Mazen Noureddin et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Shear Wave Elastography as a Quantitative Biomarker of Clinically Significant Portal Hypertension: A Systematic Review and Meta-Analysis
- (2018) Chong Hyun Suh et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Non-alcoholic Steatohepatitis is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
- (2018) Zobair Younossi et al. Clinical Gastroenterology and Hepatology
- Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated With Nonalcoholic Steatohepatitis and Fibrosis
- (2018) Donghee Kim et al. Clinical Gastroenterology and Hepatology
- Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials
- (2018) Mark Warren et al. DIABETES OBESITY & METABOLISM
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease
- (2018) Eduardo Vilar-Gomez et al. GASTROENTEROLOGY
- Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with HALTHCC improves ablate and wait strategy
- (2018) Daniel J. Firl et al. HEPATOLOGY
- Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis
- (2018) Zobair M. Younossi et al. HEPATOLOGY
- Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
- (2018) Mohammad Shadab Siddiqui et al. HEPATOLOGY
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- Insights into the Role of PPARβ/δ in NAFLD
- (2018) Jiapeng Chen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Genetics and epigenetics of NAFLD and NASH: Clinical impact
- (2018) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate
- (2018) Benaïssa Boubia et al. JOURNAL OF MEDICINAL CHEMISTRY
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- Serum testosterone and non-alcoholic fatty liver disease in men and women in the US
- (2018) Jeong Yoon Yim et al. LIVER INTERNATIONAL
- Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries
- (2018) Magnus Holmer et al. LIVER INTERNATIONAL
- Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
- (2018) Pegah Golabi et al. MEDICINE
- NASH in Nondiabetic Endocrine Disorders
- (2018) Timothy Wang et al. Metabolic Syndrome and Related Disorders
- Insights into the role of hepatocyte PPARα activity in response to fasting
- (2018) Marion Régnier et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- Direct effects of thyroid hormones on hepatic lipid metabolism
- (2018) Rohit A. Sinha et al. Nature Reviews Endocrinology
- Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma
- (2018) Erin M. Sadler et al. TRANSPLANTATION
- Pioglitazone and bladder cancer risk: a systematic review and meta-analysis
- (2018) Huilin Tang et al. Cancer Medicine
- Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review
- (2018) James G. Boyle et al. CLINICAL SCIENCE
- The gut–liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19
- (2018) Marilidia Piglionica et al. CURRENT OPINION IN PHARMACOLOGY
- Emricasan (IDN-6556) Lowers Portal Pressure in Patients with Compensated Cirrhosis and Severe Portal Hypertension
- (2018) Guadalupe Garcia-Tsao et al. HEPATOLOGY
- Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease
- (2018) Mitchell Shiffman et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Vitamin E intake and risk of stroke: a meta-analysis
- (2018) Pengfei Cheng et al. BRITISH JOURNAL OF NUTRITION
- GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
- (2018) Rohit Loomba et al. GASTROENTEROLOGY
- Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis
- (2018) Eduardo Vilar-Gomez et al. HEPATOLOGY
- Non-alcoholic fatty liver disease – A global public health perspective
- (2018) Zobair M. Younossi JOURNAL OF HEPATOLOGY
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
- (2018) Edgar D. Charles et al. Obesity
- Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis
- (2018) Tannous K. Fakhry et al. Surgery for Obesity and Related Diseases
- Future Trends in Demand for Liver Transplant
- (2018) Alexandra Shingina et al. TRANSPLANTATION
- Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions
- (2018) Peter E. Penson et al. Journal of Cachexia Sarcopenia and Muscle
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
- (2017) Rohit Loomba et al. HEPATOLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease
- (2017) Raj Vuppalanchi et al. HEPATOLOGY
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
- (2017) Parambir S. Dulai et al. HEPATOLOGY
- Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
- (2017) Hannes Hagström et al. JOURNAL OF HEPATOLOGY
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2017) David C. Tully et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
- (2017) Mukul R. Jain et al. LIVER INTERNATIONAL
- Pioglitazone and bladder cancer: FDA's assessment
- (2017) Christian Hampp et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
- (2017) Bo Ahrén et al. Lancet Diabetes & Endocrinology
- The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway
- (2017) Yasmeen M. Attia et al. Scientific Reports
- Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis
- (2016) S. A. Harrison et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Hepatic manifestations of women with polycystic ovary syndrome
- (2016) Mei-Jou Chen et al. BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY
- Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities
- (2016) Giovanni Musso et al. DIABETES CARE
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
- (2016) Yaron Rotman et al. GUT
- Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome
- (2016) D. Macut et al. HUMAN REPRODUCTION
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
- (2016) Eric Lefebvre et al. PLoS One
- Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies
- (2015) Siddharth Singh et al. Clinical Gastroenterology and Hepatology
- Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, and Hepatocellular Carcinoma
- (2015) Mazen Noureddin et al. Clinics in Liver Disease
- FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease
- (2015) Rotonya M. Carr et al. Current Atherosclerosis Reports
- The FXR-FGF19 Gut–Liver Axis as a Novel “Hepatostat”
- (2015) Matias A. Avila et al. GASTROENTEROLOGY
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
- (2015) Paul Angulo et al. GASTROENTEROLOGY
- Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
- (2015) Mattias Ekstedt et al. HEPATOLOGY
- Automatic quantification of lobular inflammation and hepatocyte ballooning in nonalcoholic fatty liver disease liver biopsies
- (2015) Scott Vanderbeck et al. HUMAN PATHOLOGY
- Prediction of prevalent but not incident non-alcoholic fatty liver disease by levels of serum testosterone
- (2015) Nam Kyoung Seo et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
- (2015) Jessica E. Potts et al. PLoS One
- Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding to Reduce Nonalcoholic Fatty Liver Disease
- (2014) Robert Caiazzo et al. ANNALS OF SURGERY
- The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease
- (2014) Rifaat Safadi et al. Clinical Gastroenterology and Hepatology
- Are Women With Polycystic Ovarian Syndrome at a High Risk of Non-Alcoholic Fatty Liver Disease? A Meta-Analysis
- (2014) Mahdi Ramezani Binabaj et al. Hepatitis Monthly
- Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia
- (2014) Martha J. Kelly et al. JOURNAL OF MEDICINAL CHEMISTRY
- Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review
- (2014) Bogna Grygiel-Górniak Nutrition Journal
- Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis
- (2014) Giovanni Musso et al. PLOS MEDICINE
- Dual Peroxisome Proliferator-Activated Receptor / Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
- (2013) B. Cariou et al. DIABETES CARE
- Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma
- (2013) Kai Wang et al. HEPATOLOGY
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2013) Bart Staels et al. HEPATOLOGY
- Automatic classification of white regions in liver biopsies by supervised machine learning
- (2013) Scott Vanderbeck et al. HUMAN PATHOLOGY
- The TGR5 receptor mediates bile acid–induced itch and analgesia
- (2013) Farzad Alemi et al. JOURNAL OF CLINICAL INVESTIGATION
- Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
- (2013) Matthew J Armstrong et al. BMJ Open
- Bile Acids Activate YAP to Promote Liver Carcinogenesis
- (2013) Sayeepriyadarshini Anakk et al. Cell Reports
- Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma
- (2012) Hongying Su et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2
- (2012) Kouichi Miura et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease
- (2012) Sunmi Kim et al. BMC GASTROENTEROLOGY
- Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy
- (2012) Rohit Anthony Sinha et al. JOURNAL OF CLINICAL INVESTIGATION
- In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not
- (2012) Zobair M. Younossi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- FXR Controls the Tumor Suppressor NDRG2 and FXR Agonists Reduce Liver Tumor Growth and Metastasis in an Orthotopic Mouse Xenograft Model
- (2012) Ulrich Deuschle et al. PLoS One
- Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening
- (2011) Eric T. Sawey et al. CANCER CELL
- Prevalence of Hypothyroidism in Nonalcoholic Fatty Liver Disease
- (2011) Mangesh R. Pagadala et al. DIGESTIVE DISEASES AND SCIENCES
- Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?
- (2011) Kathleen E. Corey et al. HEPATOLOGY
- Vitamin E and the Risk of Prostate Cancer
- (2011) Eric A. Klein et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dietary Intakes of Antioxidant Vitamins and Mortality From Cardiovascular Disease
- (2011) Yoshimi Kubota et al. STROKE
- Genome-Wide Association Study Identifies Variants Associated With Histologic Features of Nonalcoholic Fatty Liver Disease
- (2010) Naga Chalasani et al. GASTROENTEROLOGY
- Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease
- (2010) Brent A. Neuschwander-Tetri et al. HEPATOLOGY
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome
- (2009) Malgorzata M Brzozowska et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance
- (2008) Justin I. Odegaard et al. Cell Metabolism
- Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management
- (2008) Raj Vuppalanchi et al. HEPATOLOGY
- Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers
- (2008) Scott M. Lippman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation